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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A362perform a quantitative proteomics approach to identify and quantify
those proteins released from normal (N) and OA human articular car-
tilages capable of predicting the early stage of hip and knee OA.
Methods: Tissue explants were obtained from the dissection of 4 N and
4 OA cartilages, both from 2 femoral heads and 2 tibial condyles. Among
the OA samples, we differentiated the wounded zones (WZOA) from
those corresponding to the area adjacent to the lesion, or unwounded
zones (UWOA). Cartilage shavings from each donor were cut into 6 mm
discs and three discs/donor were placed into 96-well plates and cul-
tured during 6 days. The conditioned media from each condition (N,
WZOA and UWOA) were collected and their proteins were digested
with trypsin. The resulting peptides were labelled with different iso-
baric tags using the iTRAQ reagents (ABSciex). Then, labelled peptides
from the different conditions were mixed, desalted and separated by
liquid chromatography (LC). The resulting fractions were grouped and
resolved by reversed-phase nano-LC coupled to mass spectrometry
(MS). The identiﬁcation and relative quantiﬁcation of the proteins was
carried out with Protein Pilot 3.0 software.
Results: Globally we were able to identify 186 proteins released from
the cartilage explants. After statistical analysis we found secreted pro-
teins showing differences in abundance (0.7 ratio 1.3, p 0.05)
between the different OA zones (WZOA and UWOA) and N samples
from the different joints. We classiﬁed them into 3 sets of proteins: a
ﬁrst group of proteins modulated speciﬁcally in UWOA sample (early
OA biomarkers); a second group of proteins altered only in WZOA
samples (late OA biomarkers), and ﬁnally a third groupmodiﬁed in both
OA zones (progression biomarkers). Some of these modulated proteins
are common early and progression biomarkers for both hip and knee OA
(table1). Furthermore, we also identiﬁed that the release of cartilage
intermediate layer protein 1 (CILP-1), a protein involved in cartilage
scaffolding, is increased in UWOA from hip OA cartilage but not in
UWOA from knee OA, being a possible early speciﬁc biomarker for hip
OA. This speciﬁc modulation was conﬁrmed by Real-time PCR and
western blot in other human cartilage samples (n¼3).
Conclusions: We describe a novel panel of cartilage-secreted proteins
with potential biomarker value. Interestingly, we have identiﬁed a
speciﬁc protein, which speciﬁcally indicates hip OA onset. This protein
is now being explored in biological ﬂuids (synovial ﬂuid and serum) for
the development of early diagnosis and/or anti-OA therapy monitoring
strategies.Table 1
A panel of different type of potential protein biomarkers of hip OA(H) and knee OA(K) is listed in the table. Proteins showing a gradual increase among OA samples is indicated
as early and progression biomarkers. CLIP-1 speciﬁcally indicates hip OA.
Protein Name Uniprot symbol Joint peptides (95%) Ratio UWOA/N p value Ratio WZOA/N p value OA biomarker type
Pigment epithelium-derived factor PEDF H 25 2,35 0,00 4,73 0,00 Early and progression
K 32 2,31 0,00 3,16 0,00
Tenascin TENA H 60 2,99 0,00 5,03 0,00 Early and progression
K 65 1,68 0,00 6,01 0,00
Tenascin-X TENX H 28 3,21 0,00 6,84 0,00 Early and progression
K 52 1,34 0,02 2,38 0,00
Tetranection TNT H 15 2,63 0,00 3,68 0,00 Early and progression
K 16 1,96 0,01 3,52 0,00
Transforming growth factor-beta
included protein lg-h3
BGH3 H 24 5,34 0,00 6,12 0,00 Early and progression
K 23 1,57 0,00 3,55 0,00
Vimentin VIM H 22 3,69 0,00 5,13 0,00 Early and progression
K 30 1,40 0,00 4,85 0,00
Cartilage intermediate layer protein 1 CILP-1 H 142 2,27 0,00 1,02 0,83 Early
K 102 1,27 0,00 1,06 0,46 -595
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Purpose: Hyaluronic acid (HA), lubricin, and phospholipids contribute
independently or together to the boundary lubrication of articular
joints that is provided by synovial ﬂuid (SF). In our present study wefocused on the two widespread joint diseases, osteoarthritis (OA) and
rheumatoid arthritis (RA). With use of sophisticated analytical methods
our study aimed to quantify the various molecular weight (MW) forms
of HA, lubricin, and all phospholipid species. Notably, we quantiﬁed
these lubricants for the ﬁrst time in parallel in knee SF from cohorts of
healthy donors, patients with early (eOA) or late (lOA) stage osteo-
arthritis, and patients with active RA.
Methods: Only patients fulﬁlling the inclusion criteria were included in
the study. This study was approved by the ethical review committee of
the Faculty of Medicine (Justus-Liebig-University of Giessen, Germany).
Cell- and cellular debris-free SF samples from unaffected controls, eOA,
lOA, and RA were used for this study. HA and lubricin levels were
measured by sandwich enzyme-linked immunosorbent assay (ELISA).
Electrospray ionization tandem mass spectrometry was used to quan-
tify phospholipid species, and fatty acids (FAs) were analyzed by gas
chromatography, coupled with mass spectrometry. The MW dis-
tribution of HA was determined by horizontal agarose gel electro-
phoresis followed by densitometry. One way ANOVA and Tukey’s
honestly signiﬁcant difference procedure were applied to determine
statistical signiﬁcant differences. P values of less than 0.05 were con-
sidered to be statistically signiﬁcant.
Results: We provide a novel, comprehensive overview of all lubricants
present in normal, OA and RA SF, namely HA, lubricin, and phospholi-
pids. Compared with control SF, the concentrations of HA and lubricin
were signiﬁcantly lower in eOA, lOA and RA SF, whereas those of
phospholipids were higher. Moreover, compared with control SF, the
MW distribution of HA shifted towards the lower range of below 1.1
MDa in eOA, lOA and RA SF. Notably, positive correlations were
observed in eOA SF between the concentrations of HA and lubricin, and
in lOA SF between the levels of HA and phospholipids. Moreover, in eOA
SF an elevated percentage of degraded HA was associated with lower
levels of lubricin. Remarkably, we noted distinct alterations between
cohorts with respect to the relative distribution of phospholipid species
and the degree of FA saturation and chain lengths of FAs.
Conclusions: This investigation reports for the ﬁrst time a compre-
hensive overview of all lubricants present in human SF, namely HA,
lubricin, and phospholipids. The levels, composition, and MW dis-
tribution of these lubricants vary with widespread joint diseases and
stage of OA. Thus, our study provides the framework to develop new
and optimal compounded lubricants able to reduce joint destruction.596
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Purpose: We have previously used quantitative proteomics for a
detailed study of different normal cartilage subtypes to increase our
knowledge of structure in relation to biology and function. In this work
we studied changes in protein abundance in hip cartilage between
osteoarthritis (OA) and fracture patients by using the increased sensi-
tivity of targeted proteomics technology.
Methods: Site matched femoral head articular cartilage from both OA
joint replacement patients selecting the macroscopically normal tissue
